Patients battling certain lung, skin and kidney cancers may benefit from a new type of cancer treatment that harnesses and boosts a patient's immune system to shrink tumors, if early research pans out.
For the first time, patients with the deadliest form of skin cancer have two new treatment options that prolong survival, according to new research presented at a cancer conference in Chicago on Sunday.
Each spring brings major medical meetings from the likes of the American Association for Cancer Research, the American Urological Association and the American Society for Clinical Oncology, to name a few.
Lung cancer patients who are 70 years or older should be considered for a more aggressive chemotherapy treatment offered to patients who are decades younger, according to a new study presented at a major cancer conference Saturday.
Most men 50 and older should seriously consider the potential risks of treatment before deciding whether to be screened for prostate cancer, the American Cancer Society said Wednesday in revised guidelines.
For the first time, doctors said Monday they have found a pill that improves survival for people with liver cancer, a notoriously hard to treat disease diagnosed in more than half a million people globally each year
Sutent, an anti-cancer drug from Pfizer that's been on the market just a few months, shrank tumors and stopped them from spreading in the lungs and kidneys of patients, according to studies unveiled this weekend.
The Sanofi-Aventis blockbuster Taxotere improves the chance of survival by 30 percent for patients with head and neck cancer, a lead researcher said Sunday, possibly leading to additional sales for the French drug giant.
Pfizer is planning to launch a new drug, possibly by year-end, to treat a rare but deadly form of stomach cancer, that could bring in up to $800 million a year for the world's biggest drugmaker, an industry analyst said Monday.